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I n t r o d u c t I o n
Smoking is the leading cause of preventable death in the world and hence sig-
nificant effort is made in order to promote, assist and maintain smoking cessation. 
Several methods have been recruited to this cause. Behavioral therapy had a relatively 
modest effect.1 Drug interventions used nicotine replacement therapy (NRT) which 
reduces the symptoms of nicotine withdrawal, anti-depressant therapy with bupropion 
(marketed by GlaxoSmithKline as Zyban and other names), a weak dopamine and nor-
epinephrine reuptake inhibitor to counteract depression caused by smoking cessation, 
and varenicline (trade name Chantix in the USA and Champix in Europe, marketed 
by Pfizer) which is a nicotinic acetylcholine receptor partial agonist. Its mechanism 
of action is considered to be stimulating release of dopamine to reduce craving and 
withdrawal and at the same time blocking the full spectrum of neurobiological effects 
of smoked nicotine.2-4 Data from meta-analyses show odds ratios for smoking ces-
sation ranging from 1.6 for bupropion to 2.96 for varenicline, always in favor of the 
intervention, in 12 months.5 However, despite the effectiveness of these therapies, rates 
of smoking remain high at one year in the treatment groups and the development of 
novel methods is warranted.6
E l E c t r o n I c  c I g a r E t t E
Electronic cigarette (e-cigarette) has been marketed as a smokeless alternative to 
conventional cigarette, cheaper and safer, and as a potential cessation method and it 
gained significant popularity quickly. Sales from the e-cigarette market doubled from 
$250 to $500 million between 2011 and 2012, and are expected to quadruple by 2014.7 
However, certain legal issues have arisen since e-cigarettes contain nitrosamines, 
diethylene glycol, and other potentially harmful substances.8 The Food and Drug 
Administration in the US suggested that the sale of e-cigarettes should be prohibited 
or regulated as dangerous nicotine delivery systems and the US Court of Appeals de-
cided that e-cigarettes may not be marketed as a safer alternative to cigarettes, or as 
a smoking cessation device, but instead must be sold as a smokeless tobacco product 
subject to the same rules and regulations of other tobacco products.9,10
The chemical analysis of the solution and vapor of e-cigarettes, which represents 
the potential perils from extended use, is also controversial. In most of the studies 
their ingredients are non-toxic and non- carcinogenic, especially in the low quantities 
delivered. They include nicotine, propylene glycol, glycerin, and tobacco flavoring. A 
small amount of diethylene glycol (approximately 1%), a known carcinogen and an 
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ingredient in anti-freeze, has also been detected.11 It is useful 
to note that smoke of traditional cigarettes contains thou-
sands of compounds, such as heavy metals (cadmium, arsenic, 
chromium, nickel, and lead), tobacco specific N-nitrosamines 
(TSNA), polycyclic aromatic hydro- carbons and volatile or-
ganic compounds many of which have been shown to induce or 
promote carcinogenesis.12 Some of these substances have been 
detected in e-cigarette solutions and mist but only scarcely have 
their levels been high enough to be considered dangerous.13,14 
Williams at al found levels of lead, chromium, and nickel in e-
cigarette aerosol to be equivalent to, and in some cases higher 
than, what has been reported for cigarette smoke.15
The physiological effects of vaping also display certain 
discrepancies in different studies. Most of them show that 
nicotine levels are considerably lower after e-cigarette use 
than smoking a conventional cigarette, although others report 
similar effects between vaping and smoking.16-21 With regard 
to clinical effects, the majority of researchers conclude that 
e-cigarette mist is less harmful. It has been shown less cyto-
toxic for embryonic stem cells and murine fibroblasts, and it 
produces smaller changes in functional pulmonary parameters. 
Moreover, Flouris et al demonstrated that acute smoking, but 
not acute vaping, induced increases in white blood cell count, 
lymphocyte count and granulocyte count; in a case report 
Farsalinos and Romagna reported that smoking cessation 
and e-cigarette use reversed symptoms of chronic idiopathic 
neutrophilia.22-25
In contrast to these results, Vardavas et al showed that 
five minutes of acute vaping induced a decrease in exhaled 
nitric oxide and an increase in airway resistance and imped-
ance in experienced smokers, while quitting of vaping cured 
an exogenous lipid pneumonia in a case report by McCauly et 
al.26,27 Furthermore, a study in in vitro cultures of pulmonary 
fibroblasts and human embryonic stem cells displayed cyto-
toxic effects of chemical compounds contained in electronic 
cigarette devices.28
Hence, the so far collected data with respect to the physi-
ological and clinical effects of vaping are somewhat discrepant. 
Most reports advocate for a rather neutral impact on health 
and certainly suggest substantially less harm in comparison to 
smoking which is estimated at approximately 1% of the mortal-
ity risk of smoking.29,30 However, the publications indicating 
the negative effects of e-cigarettes cannot be ignored and 
the issue is still open until more trials evaluate the long-term 
consequences of their use.
A more prudent approach would be to invest on vaping 
as a tool in smoking cessation efforts, since this would prob-
ably require a short- to mid- term exposure to e-cigarette 
compounds, hopefully not exceeding 12 months. A 12-month 
study which randomized 300 smokers with no intention to quit 
smoking to two different e-cigarette dosing regimens and a 
placebo e-cigarette without nicotine, showed smoking reduc-
tion 22.3% and 10.3% at week-12 and week-52 respectively 
and complete abstinence from tobacco smoking 10.7% and 
8.7% at the same time intervals in all three groups without 
differences among them.31
The same team conducted a small trial in 14 schizophrenic 
patients and showed sustained 50% reduction in the number 
of cigarettes/day at week-52 in 7/14 (50%) participants (from 
a median of 30 to 15 cigarettes/day, p = 0.018) and sustained 
smoking abstinence at week-52 2/14 (14.3%) of the study 
population.32 Polosa et al followed 40 smokers started on elec-
tronic cigarette for 6 months and found 50% reduction in the 
number of cigarettes/day in 13/40 (32.5%) of them (from 25 
to 6 cigarettes/day, p <0.001), 80% reduction in 5/40 (12.5%) 
and complete smoking abstinence in 9/40 (22.5%).33
In an online survey with a total of 222 respondents, at 
the end of a 6-month period, smoking abstinence was 31.0% 
(95% CI=24.8%, 37.2%). Smoking reduction reached 66.8% 
and temporary cessation was observed in nearly 50% of the 
sample. The number of e-cartridges used per day correlated 
with the outcome, a finding confirmed by others as well but 
not invariably present.34 Interestingly, one third of the respond-
ers did not use any nicotine containing products at the time 
of evaluation.35
A large trial with 657 participants compared the efficacy 
of e-cigarette with or without nicotine and nicotine patches 
by randomizing the study population in three groups in a 4:4:1 
ratio (289 to nicotine e-cigarettes, 295 to patches, and 73 to 
placebo e-cigarettes) administered from one week prior to 12 
weeks after smoking quit. At 6 months, biochemically verified 
abstinence was 7.3% with nicotine e-cigarettes, 5.8% with 
patches, and 4.1% with placebo e-cigarettes. The efficacy of all 
three methods was similar with the risk difference for nicotine 
e-cigarette vs patches being 1.51 (95% CI -2.49 to 5.51) and for 
nicotine e-cigarettes vs placebo e-cigarettes 3.16 (95% CI -2.29 
to 8.61).36 However, even in this trial the smoking cessation rate 
was lower than expected, leading to reduced statistical power 
and inability to elicit established conclusive results.
c o n c l u S I o n
The electronic cigarette has gained significant popular-
ity among smokers both as a substitute for conventional 
tobacco use and as an aid to smoking cessation. The delivery 
of harmful substances and elements via e-cigarette use seems 
substantially lower compared with conventional smoking but 
the effects of vaping in health status, especially after prolonged 
administration have not been fully elucidated yet. Therefore, a 
prolonged use of e-cigarettes as a substitute for conventional 
smoking is not advisable until more trials assess their long-term 
consequences. A more sensible ambition would be to employ 
vaping as a bridge to quitting, providing that after a reasonable 
time period e-cigarette will be discontinued as well. The initial 
trials have been encouraging towards this direction but more 
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research is needed to define the exact position of electronic 
cigarette in contemporary preventive medicine.
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